Clinical trial, meta-analysis find diabetes drugs may benefit all heart failure patients
A meta-analysis of clinical trials found that SGLT2 inhibitors, like dapagliflozin and empagliflozin, reduce cardiovascular death and hospitalization in patients with mildly reduced or preserved ejection fraction heart failure. These drugs may benefit a wide range of patients, regardless of age, sex, or medical history.
SourceBrigham and Women's Hospital·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateAug 27, 2022